Objective: The aim of this study was to investigate the renoprotective effects and molecular mechanisms of astragaloside IV (AS-IV) in streptozotocin (STZ)-induced diabetic mice. Methods: Male C57BL/6 mice were injected intraperitoneally with STZ at 200 mg/kg body weight. AS-IV was administered for 8 consecutive weeks, beginning 1 week after STZ injection. Body weight, 24-hour urinary albumin excretion, and fasting blood glucose were measured. Kidney tissues were examined by histopathological analyses. Total levels and phosphorylation of mitogen-activated protein kinase 1/2 (MEK1/2), extracellular signal-regulated kinases 1 and 2 (ERK1/2), and ribosomal S6 kinase 2 (RSK2) were determined by Western blotting analysis. Results: AS-IV treatment significantly reduced albuminuria and serum creatinine levels, ameliorated mesangial matrix expansion and greater foot process width, and decreased the levels of urinary N-acetyl-beta-D-glucosaminidase, neutrophil gelatinase-associated lipocalin, and transforming growth factor-beta 1 in STZ-induced diabetic mice. AS-IV also inhibited renal cortical phosphorylation of MEK1/2, ERK1/2 and RSK2. 
Introduction
Diabetic nephropathy (DN), one of the most serious microvascular complications associated with diabetes mellitus (DM), has become the predominant cause of endstage renal disease (ESRD) worldwide. [1] [2] [3] The early abnormalities of DN include hyperfiltration and microalbuminuria. These abnormalities are followed by histological and structural changes, including mesangial expansion and thickening of the glomerular basement membrane (GBM). 4 The precise pathogenesis of DN has not yet been fully elucidated. The measures most commonly used in the treatment of DN include strict control of hyperglycemia and blood pressure, as well as the use of renin-angiotensin-aldosterone system (RAS) blockers. 5, 6 However, these treatments are not effective at preventing disease progression, and there is a pressing need for the development of novel therapeutics that inhibit the progression of DN.
Mounting evidence suggests that the development of DN is associated with the concomitant activation of several stresssensitive signal pathways, including mitogen-activated protein kinase (MAPK) cascades. As principal members of the MAPK family, extracellular signalregulated kinases 1 and 2 (ERK1/2) have been shown to play a crucial role in cell proliferation and extracellular matrix protein synthesis. 7 Previous studies confirmed that ERK1/2 is activated in glomeruli of diabetic rats and mesangial cells cultured under high-glucose conditions. 8, 9 The inhibition of ERK1/2 and associated downstream cascades confers a protective effect against DN. 10, 11 Traditional Chinese medicines (TCM) have long been applied for intervention in different diseases. [12] [13] [14] [15] In particular, Astragalus membranaceus (Fisch) Bge has been widely used in TCM for thousands of years; astragaloside IV (AS-IV) is one of its most important and active constituent compounds. Increasing in vitro and in vivo evidence suggests that AS-IV could alleviate kidney injury. 16, 17 In addition, several reports have suggested that AS-IV may exert beneficial effects in DN through these pleiotropic activities. 18 However, the exact molecular mechanisms that underpin these effects remain unclear. Recent studies have demonstrated that the renoprotective effects mediated by AS-IV are associated with MAPK pathways. 19 Our previous study demonstrated that AS-IV can suppress the activation of ERK1/2 in db/db mice. 18 To the best of our knowledge, there have been no reports of the activation of ERK1/2 and its up-and downstream targets in the streptozotocin (STZ)-induced early-stage DN model. In the present study, we investigated the renoprotective mechanisms of AS-IV by inhibiting activation of MEK1/2-ERK1/2-RSK2 signaling in STZ-induced type 1 DN.
Materials and methods

Animal model and drug treatment
Healthy male C57BL/6 mice (5 to 6 weeks old) weighing 16 to 18 g were purchased from the Guangdong Medical Laboratory Animal Center. All animal studies were performed in accordance with the NIH statements regarding "Principles of Laboratory Animal Care" and were approved by the Guangzhou University of Chinese Medicine Institutional Animal Care and Use Committee. Mice were housed at constant room temperature (20 AE 1 C) under a controlled 12:12-hour light-dark cycle; they were fed a standard diet and given free access to water. Mice were randomly divided into the following three groups (n¼8 to 10 per group): control mice (control group), STZ-induced diabetic mice, and diabetic mice who were fed a diet supplemented with AS-IV (AS-IV-treated mice). Experimental diabetes was induced in mice, following 4 hours of fasting, by a single intraperitoneal injection (200 mg/kg) of streptozotocin (STZ, Sigma-Aldrich, St. Louis, MO, USA) dissolved in 0.1 M citrate buffer (pH 4.2). Normal control mice were intraperitoneally injected with an equal volume of vehicle. At 1 week after STZ injection, tail vein blood was collected for blood glucose measurements. Mice with fasting blood glucose concentrations >16.7 mmol/L were considered diabetic mice. AS-IV administration was initiated at 1 week after STZ injection. AS-IV, purchased from Cheng Du Con Bon Biotech Co., LTD (Chengdu, China), was added to the standard chow at 5 g/kg diet. The treatment period lasted for 8 weeks.
Metabolic parameters and tissue preparation
Every two weeks, each mouse was weighed and blood samples were obtained by tail vein puncture for blood glucose measurements by using a blood glucose meter (Roche, Basel, Switzerland). Mice were kept in metabolic cages (Tecniplast S.p.a, Buguggiate, Italy) to facilitate the collection of 24-hour urine samples at 4 and 8 weeks of treatment. At the end of 8 weeks of treatment, mice were sacrificed; blood samples and kidney tissues were harvested immediately. Urine and serum biochemical parameters, including blood urea nitrogen (BUN), serum creatinine (Scr), urine creatinine (Ucr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total protein (TP), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), urinary glucose, and urinary N-acetyl-b-d-glucosaminidase (NAG) were measured by using a Roche automatic biochemical analyzer. Urinary albumin to creatinine ratio (UACR) was calculated and presented as urine albumin (mg) divided by Ucr (g). At the time of sacrifice, excised kidneys were weighed and rinsed in phosphate buffer solution. The left kidney was sliced into two parts to facilitate histopathology analyses. The right kidney was immediately snap-frozen in liquid nitrogen and stored at À80 C for additional analyses.
Enzyme-linked immunosorbent assay (ELISA)
Urinary albumin (Bethyl Laboratories, Montgomery, TX, USA), urinary neutrophil gelatinase-associated lipocalin (NGAL; R&D Systems, Minneapolis, MN, USA), urinary transforming growth factor-beta 1 (TGF-b1; R&D Systems), and serum insulin (Merck, Darmstadt, Germany) ELISA kits were used in accordance with the manufacturers' instructions.
Light microscopy
Kidneys were fixed with 10% buffered formalin, embedded in paraffin, cut into 2-mm sections and stained with periodic acidSchiff (PAS) reagent to evaluate glomerular and tubular alterations. For each section, 30 to 60 renal glomerular tuft areas (GTA), 30 renal glomerular mesangial matrix areas, 80 to 110 renal tubular areas and tubular lumen areas (axial ratio less than 1.5) were measured by using NISElements imaging software Version 4.10 (Nikon Corporation, Tokyo, Japan).
Electron microscopy
After incubation on ice, the renal cortex was cut into 1-mm 3 sections; these sections ("tissue fragments") were immediately fixed in 2.5% glutaraldehyde. Tissue fragments were postfixed with 1% osmic acid, dehydrated with graded ethanol, and then embedded in Epon. Ultrathin sections (50 to 70 nm) were subsequently stained with uranyl acetate and lead citrate, then examined by electron microscopy (EM). ImageJ software (National Institutes of Health, Bethesda, MD, USA) was used to analyze images collected by EM (JEM-1400, JEOL Ltd., Tokyo, Japan) under 12,000Âmagnification. Glomerular basement membranes (GBM) and tubular basement membranes (TBM) (10 to 13 photographs per sample, n¼3 per group) were measured by using the grid intersect method. Average podocyte foot process width (FPW) was measured by using the following formula: FPW ¼ (p/4) Â (RGBM length/R number of foot process). The FPW (6 to 13 photographs per sample, n¼3 per group) values were subsequently presented in nanometers (nm).
Western blotting analysis
Snap-frozen renal cortical tissue was homogenized in lysis buffer as previously described. [20] [21] [22] Equal amounts of sample (20 mg) were separated on 10% sodium dodecyl sulfate (SDS)/polyacrylamide gels, then transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA). Nonspecific binding was blocked by incubating the membranes at room temperature for 1 hour with 5% non-fat milk in Trisbuffered saline (TBS). The membranes were subsequently incubated overnight at 4 C with the following primary antibodies:
. b-actin (Sigma-Aldrich) was used as a loading control. After washing three times with TBS, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour at room temperature with shaking. Protein bands were visualized and analyzed by using a ChemiDoc TM MP Imaging System (BioRad Laboratories). Results were expressed as the integrated optical density relative to b-actin.
Statistical analysis
Statistical analyses were conducted by using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). All data were expressed as means AE standard deviation (SD). Statistically significant differences between two groups were evaluated by using Student's t-test. Differences between multiple groups were determined by one-way ANOVA analysis of variance, followed by post hoc Tukey test. Data were considered to be statistically significant if P < 0.05.
Results
AS-IV significantly attenuates albuminuria in diabetic mice
Compared with control mice, 24-hour urinary albumin excretion and UACR were significantly increased in diabetic mice at 4 and 8 weeks (both P < 0.001; Figure 1a-b) . Following treatment with AS-IV for 4 weeks, 24-hour urinary albumin excretion (P<0.01) and UACR (P<0.05) were markedly reduced; this effect continued through 8 weeks of treatment with AS-IV (both P < 0.05; Figure 1a -b).
Physiological parameters and serum levels of biochemical markers
As shown in Table 1 , STZ-induced diabetic mice exhibited polydipsia, polyuria, polyphagia, and increased fecal production, following treatment with STZ. AS-IV administration did not relieve these symptoms. Diabetic mice exhibited elevated blood glucose, compared with control mice, during the entire study period (P < 0.001 for all time points; Figure 2a ). At 8 weeks of treatment with AS-IV, diabetic mice demonstrated significantly higher urinary glucose and lower serum insulin, compared with control mice (both P < 0.001; Figure 2b -c). However, no significant differences were found in these parameters between diabetic mice and AS-IV-treated mice (Figure 2a-c) . Levels of Scr and BUN in diabetic mice were substantially higher than in control mice. AS-IV administration significantly reduced Scr levels after 8 weeks of treatment (P < 0.05; Table 2 ). Compared with control mice, diabetic mice exhibited significantly higher TG (P < 0.05) and slightly lower HDL-C. Treatment with AS-IV resulted in an increase in HDL-C (P < 0.01), but no change in TG. In addition, no difference in LDL-C was observed among the three groups at 8 weeks after AS-IV administration ( Table 2) .
Effects of AS-IV on glomerular hypertrophy and injury in diabetic mice
Diabetic mice exhibited decreased body weight, compared with control mice, after STZ induction (P < 0.001 for all time points; Figure 3a) . However, no difference in body weight was detected between diabetic mice and AS-IV-treated mice (Figure 3a) . Results are represented as mean AE SD (n ¼ 6 per group). ***P < 0.001 between the control and the streptozotocin (STZ) group; # P < 0.05 and ## P < 0.01 between the STZ and the STZþ AS-IV groups. ᭝᭝᭝ P < 0.001 between the control and the STZþ AS-IV groups. Results are expressed as the mean AE standard deviation (n ¼ 6/each group). *P < 0.05, **P < 0.01, and ***P < 0.001 vs. normal control group. Streptozotocin (STZ), astragaloside IV (AS-IV).
Figure 2. Astragaloside IV (AS-IV) had no effect on fasting blood glucose, urinary glucose and serum insulin in diabetic mice. Effects of AS-IV on blood glucose levels throughout the study (a). Effects of AS-IV on urinary glucose (b) and serum insulin (c) after 8 weeks of treatment. Results are represented as mean AE SD (n ¼ 6 per group). ***P < 0.001 between the control and the streptozotocin (STZ) groups. ᭝᭝᭝ P < 0.001 between the control and the STZþ AS-IV groups.
Kidney weight (expressed as kidney weight/ body weight) was significantly greater in diabetic mice than in normal mice at the end of the study (P < 0.001; Figure 3b ). However, kidney weight was only slightly reduced after 8 weeks of treatment with AS-IV, compared with kidney weight in untreated diabetic mice (Figure 3b) . At 8 weeks, diabetic mice exhibited larger GTA, higher mesangial matrix ratios, thicker GBM, and greater FPW, compared with control mice (P < 0.01 for GTA, P < 0.05 for all others; Figure 4a-d) . AS-IV treatment significantly ameliorated the diabetic changes in GTA, mesangial matrix, and FPW (P < 0.05 for all; Figure 4a-b, d ). However, AS-IV had no obvious effect on GBM (Figure 4c) . PAS staining and EM were used to evaluate these characteristics in each group (Figure 4e) . Results are expressed as the mean AE standard deviation (n ¼ 6/each group). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. normal control group. Astragaloside IV (AS-IV) had no effect on body weight and kidney weight in diabetic mice. Effects of AS-IV on body weight throughout the study (a). Effects of AS-IV on kidney weight after 8 weeks of treatment (b). ***P < 0.001 between the control and the streptozotocin (STZ) groups.
᭝ P < 0.05 and ᭝᭝᭝ P < 0.001 between the control and the STZþ AS-IV groups. 
Effects of AS-IV on tubular injury in diabetic mice
Compared with control mice, diabetic mice showed a significant increase in urinary levels of NGAL, NAG, and TGF-b1 at 8 weeks (P < 0.001 for all; Figure 5a-c) . AS-IV administration resulted in a significant reduction in urinary NGAL and NAG (both P < 0.05); no significant differences in TGF-b1 were found after 8 weeks of treatment (Figure 5c ). Histomorphological changes in the proximal tubules of the kidneys were also investigated. Compared with control mice, the proximal tubular area and lumen were slightly larger and the TBM was thicker (P < 0.05) in diabetic mice (Figure 5d-f) . AS-IV treatment reduced these histopathological alterations, although no statistically significant differences were found in TBM and proximal tubular lumen (Figure 5d-f) . PAS staining and EM were used to evaluate these characteristics in each group (Figure 5g ).
AS-IV inhibits renal cortical overexpression of MEK1/2-ERK1/2-RSK2 signaling pathway proteins in diabetic mice
Expression levels of p-MEK1/2 (ser217/ 221), p-ERK1/2(Thy202/Tyr204), and p-RSK2 (Ser227) were significantly upregulated in diabetic model mice, compared with control mice (P < 0.01 for all; Figure 6a-f) . However, total RSK2, ERK1/2, and MEK1/2 protein levels did not substantially change, as indicated by western blot analysis (Figure 6a, c, e) . In AS-IV-treated mice, activation of these proteins was significantly inhibited after 8 weeks (P < 0.01 for all; Figure 6a -f).
AS-IV does not cause apparent toxicity to the liver Diabetic mice showed significantly higher ALT (P < 0.001) and AST (P < 0.05), and significantly lower ALB and TP (both P < 0.001), compared with control mice. There were no significant differences in these parameters between diabetic mice and AS-IV-treated mice (Table 2) , which indicates that AS-IV did not cause apparent toxicity to the liver.
Discussion
In this study, we demonstrated that AS-IV exerts renoprotection in STZ-induced DN, and that the effect might be partially associated with inhibition of MEK1/2-ERK1/2-RSK2 signaling.
A strong correlation has been reported between hyperglycemia and the progression of DN. 23 Strict glycemic control can significantly reduce the risk of developing microalbuminuria and overt DN. 23 Several studies have demonstrated that AS-IV reduces blood glucose levels in STZ-induced diabetic models. 24, 25 However, in our study, and in several studies performed by other groups, AS-IV had no hypoglycemic effect on STZ-induced diabetic models. 26, 27 These conflicting results could be related to several possible factors, including AS-IV dosage, duration of AS-IV treatment, and variations among the diabetes models that were used in each study. 28 Thus, our study suggested that the renoprotective effect of AS-IV is independent of glucose control.
Microalbuminuria is a strong prognostic indicator for the progression of early DN. It is widely accepted that the underlying pathophysiological mechanisms that underpin the role of albuminuria in DN include the occurrence of structural abnormalities, such as morphologic changes in podocytes, mesangial matrix expansion, and GBM thickening. 29 Mesangial matrix expansion occurs in DN patients before the onset of clinical manifestations. 30 The degree of mesangial expansion correlates with the occurrence of glomerulosclerosis and reduced renal function. 31 Inhibition of mesangial expansion is considered a potential target in the prevention and delayed onset of DN. 32 In our study, we observed that AS-IV significantly reduces mesangial expansion caused by DN. Podocytes play a crucial role in the maintenance of the glomerular filtration barrier and in glomerular structural integrity. [33] [34] [35] [36] Increasing evidence . Data are represented as mean AE SD (n ¼ 3-6 per group). *P < 0.05 and ***P < 0.001 between the control and the streptozotocin (STZ) group. # P < 0.05 between the STZ and the STZþ AS-IV groups.
᭝ P < 0.05 and ᭝᭝᭝ P < 0.001 between the control and the STZþ AS-IV groups.
suggests that a reduction in the number of podocytes may lead to the development of proteinuria in both type 1 and type 2 diabetes. 37 This loss of podocytes would require the residual cells to cover a larger area of the GBM, which could then cause foot process widening. Widening of foot processes has been confirmed to correlate directly with microalbuminuria in type 1 DN. 38 Previous studies have indicated that AS-IV treatment ameliorated podocyte loss in STZ-induced diabetic rats. 39 However, it is unclear whether AS-IV plays a role in podocyte FPW. In our study, we observed that AS-IV significantly reduced FPW. Tubular injury has been reported as a critical component in the pathogenesis of early DN. 40 Several studies previously reported that AS-IV has a protective effect on tubular injury. 41, 42 However, there is little evidence regarding the effectiveness of AS-IV on tubular injury in STZ-induced diabetic mice. In the present study, specific tubular injury biomarkers, including NAG, NGAL, and TGF-b1, were reduced following AS-IV treatment. Consistent with these results, AS-IV ameliorated the increase in the proximal tubular area in diabetic mice.
We further investigated possible molecular mechanisms underlying the renoprotective effects associated with AS-IV treatment. Mesangial matrix expansion is largely due to the accumulation of extracellular matrix (ECM) proteins. Excessive accumulation of ECM occurs in early DN and this phenomenon contributes greatly to renal glomerular sclerosis and interstitial fibrosis. 43 Several signaling pathways are involved in ECM production, including TGF-b/Smad, Wnt/ b-catenin, PI3K/Akt, and MAPK. 21, 36, 44 The MAPK family comprises three major subgroups, namely ERK, c-jun N-terminal kinases (JNK), and p38 MAPK (p38). 45 Of these, the activated ERK1/2 pathway plays a major role in the regulation of cell growth, survival, and differentiation. 46 This pathway has a well-characterized role in regulating ECM expression. Previous studies reported that renal ERK1/2 activity was significantly increased both in DN animal models and cultured renal cells. 47, 48 ERK phosphorylation was also confirmed to be associated with the extent of glomerular lesions in human DN. 49 Furthermore, treatments used to inhibit increased p-ERK1/2 levels have been shown to ameliorate DN. 50 Consistent with previous studies, we found that p-ERK1/2 is upregulated in the kidneys of STZ-induced diabetic mice. In addition, up-and downstream modulators of p-ERK1/2, including p-MEK1/2 and p-RSK2, were increased. AS-IV has been reported to exhibit antifibrotic effects by inhibiting TGF-b1-induced phosphorylation of ERK1/2 in cultured mouse renal fibroblasts. 51 However, it is not clear whether AS-IV treatment can inhibit ERK1/2 activation in STZ-induced diabetic mice. In the present study, analysis of the underlying mechanisms elicited by AS-IV treatment showed that AS-IV dramatically suppressed phosphorylation of ERK1/2, MEK1/2, and RSK2 in STZ-induced diabetic mice. These results indicate that renoprotection caused by AS-IV treatment might be partially associated with inhibition of MEK1/2-ERK1/2-RSK2 signaling.
In conclusion, this study demonstrated that AS-IV treatment reduced urinary albumin excretion and ameliorated structural and functional abnormalities associated with diabetic kidneys in the STZ-induced diabetic mouse model. The molecular mechanisms underlying the renoprotective effects of AS-IV might be partially associated with reduced ECM deposition through inhibition of MEK1/2-ERK1/2-RSK2 signaling. Taken together, these novel findings suggest that AS-IV might serve as an alternative therapeutic agent in the treatment of early DN.
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